36-year-old Ritesh Gangwani had been grappling with severe asthma for years, going through a minimum of three intense attacks every year. Frequent nebulization sessions and reliance on various ...
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
They also need to be having at least four severe asthma attacks per year and either have not responded to, or be unable to tolerate, other biologic drugs like GlaxoSmithKline's Nucala (mepolizumab).
The three studies, led by Jeanine Buchanich and Evelyn Talbott from Pitt’s School of Public Health, link unconventional natural gas developments (UNGDs) that utilize fracking and other environmental ...
Study objectives: To document the existence and investigate the etiology of "thunderstorm asthma," which has been reported sporadically over the past 20 years. Design: We assessed the relationship ...
Secondary prevention, exemplified by allergen-specific immunotherapy, has a place in the effort to avert acute attacks; however, its use is restricted within the allergic asthma subtype.
The researchers ... Burning Incense Can Pose Health Risks for Those With Allergies and Asthma Oct. 24, 2024 — A new medically challenging case warns that, for those with allergies and asthma ...